<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186598</url>
  </required_header>
  <id_info>
    <org_study_id>1389613</org_study_id>
    <nct_id>NCT04186598</nct_id>
  </id_info>
  <brief_title>Evaluating the Utility of Continuous Positive Airway Pressure in the Treatment of High Altitude Pulmonary Edema</brief_title>
  <official_title>Multicenter Randomized Double-Blind Control Trial Evaluating the Utility of Continuous Positive Airway Pressure (CPAP) in the Treatment of High Altitude Pulmonary Edema (HAPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centura Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulmodyne, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centura Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy of continuous positive pressure on
      resolution of high-altitude pulmonary edema vs high flow oxygen. The secondary objective is
      to derive an incidence of high-altitude pulmonary edema based on the elevation and timing
      from which the subject arrives. Additionally, in a convenience sample of the base study
      population, an ultrasound evaluation for the presence of B lines in the lungs will be
      conducted after 2 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, double-blinded, randomized control trial. Enrollment is based on presentation to
      one of the treating facilities with clinical signs and symptoms of high-altitude pulmonary
      edema with a recent arrival at high altitude, an oxygen saturation below 85%, and
      radiographic evidence of noncardiogenic pulmonary edema. A total of 264 patients will be
      randomized 1:1 across 2 study arms: a CPAP mask set to 15cm H2O and an altered CPAP mask in
      which the pressure valve has been modified to deliver no positive pressure. All patients will
      be treated with 30mg nifedipine XR. Except for the application of positive pressure, all
      other interventions are performed in the context of everyday clinical practice, and thus will
      be equivalent for participants in both arms. Patients will be evaluated every 30 minutes for
      their ability to maintain an oxygen saturation of 92% with a normal respiratory rate and no
      signs of increased work of breathing on 2 liters of nasal cannula oxygen for a total of up to
      a maximum treatment length of 2 hours. The primary efficacy endpoint will be assessed every
      30 minutes for 2 hours.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Standard CPAP systems and control CPAP systems that provide high flow oxygen without PEEP</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of HAPE</measure>
    <time_frame>2 hours</time_frame>
    <description>The amount of time it took to maintain oxygen saturation over 92% on 2L NC oxygen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of ultrasound detectable B lines</measure>
    <time_frame>2 hours</time_frame>
    <description>A convenience sample of the total study population will have a bedside pulmonary ultrasound at time zero and two hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of time at altitude to development of HAPE</measure>
    <time_frame>2 hours</time_frame>
    <description>A descriptive measurement of the time since the patient arrived at altitude until the development of HAPE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HAPE by native altitude and reported sleeping altitude</measure>
    <time_frame>2 hours</time_frame>
    <description>Data will be collected and analyzed to seek a relationship between the subjects home altitude and the altitude of their sleep while at high altitude</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Continuous Positive Airway Pressure</condition>
  <condition>High Altitude Pulmonary Edema</condition>
  <arm_group>
    <arm_group_label>Experimental: CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with CPAP. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: High flow oxygen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be treated with an altered CPAP mask that will deliver high flow oxygen. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP mask system</intervention_name>
    <description>Intervention group will receive 15cm of H2O of positive end expiratory pressure</description>
    <arm_group_label>Experimental: CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine 30 MG</intervention_name>
    <description>All participants will receive this intervention</description>
    <arm_group_label>Control: High flow oxygen</arm_group_label>
    <arm_group_label>Experimental: CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP mask system without PEEP</intervention_name>
    <description>Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure</description>
    <arm_group_label>Control: High flow oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 18 years or greater

          -  Oxygen saturation below 85%

          -  Recent arrival to high altitude

          -  Dyspnea and cough

          -  Xray revealing non-cardiogenic pulmonary edema

        Exclusion Criteria:

          -  Pregnancy

          -  Age below 18

          -  Patients with respiratory failure requiring intubation

          -  Patients with altered mental status

          -  Patients with impaired decision-making capacity

          -  Patients with a history of congestive heart failure, CAD, COPD, asthma, known current
             pneumonia

          -  Extreme facial hair precluding application of CPAP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Bolotin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centura Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Todd Bolotin, MD</last_name>
    <phone>3302193838</phone>
    <email>tbolotin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Knappe, MSN</last_name>
    <phone>9704531010</phone>
    <email>HeatherKnappe@Centura.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Murdoch DR. Prevention and Treatment of High-altitude Illness in Travelers. Curr Infect Dis Rep. 2004 Feb;6(1):43-49.</citation>
    <PMID>14733848</PMID>
  </reference>
  <reference>
    <citation>Gonzalez Garay A, Molano Franco D, Nieto Estrada VH, Martí-Carvajal AJ, Arevalo-Rodriguez I. Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs. Cochrane Database Syst Rev. 2018 Mar 12;3:CD012983. doi: 10.1002/14651858.CD012983. Review.</citation>
    <PMID>29529715</PMID>
  </reference>
  <reference>
    <citation>Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003 Jun 7;361(9373):1967-74. Review.</citation>
    <PMID>12801752</PMID>
  </reference>
  <reference>
    <citation>Gallagher SA, Hackett PH. High-altitude illness. Emerg Med Clin North Am. 2004 May;22(2):329-55, viii. Review.</citation>
    <PMID>15163571</PMID>
  </reference>
  <reference>
    <citation>Nieto Estrada VH, Molano Franco D, Medina RD, Gonzalez Garay AG, Martí-Carvajal AJ, Arevalo-Rodriguez I. Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs. Cochrane Database Syst Rev. 2017 Jun 27;6:CD009761. doi: 10.1002/14651858.CD009761.pub2. Review.</citation>
    <PMID>28653390</PMID>
  </reference>
  <reference>
    <citation>Stoltzfus S. The role of noninvasive ventilation: CPAP and BiPAP in the treatment of congestive heart failure. Dimens Crit Care Nurs. 2006 Mar-Apr;25(2):66-70. Review.</citation>
    <PMID>16552275</PMID>
  </reference>
  <reference>
    <citation>Luks AM, Auerbach PS, Freer L, Grissom CK, Keyes LE, McIntosh SE, Rodway GW, Schoene RB, Zafren K, Hackett PH. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update. Wilderness Environ Med. 2019 Dec;30(4S):S3-S18. doi: 10.1016/j.wem.2019.04.006. Epub 2019 Jun 24.</citation>
    <PMID>31248818</PMID>
  </reference>
  <reference>
    <citation>Johnson PL, Johnson CC, Poudyal P, Regmi N, Walmsley MA, Basnyat B. Continuous positive airway pressure treatment for acute mountain sickness at 4240 m in the Nepal Himalaya. High Alt Med Biol. 2013 Sep;14(3):230-3. doi: 10.1089/ham.2013.1015.</citation>
    <PMID>24067184</PMID>
  </reference>
  <reference>
    <citation>Hébert PC, Stanbrook M. Indication creep: physician beware. CMAJ. 2007 Sep 25;177(7):697, 699. Epub 2007 Sep 5. English, French.</citation>
    <PMID>17823137</PMID>
  </reference>
  <reference>
    <citation>Walmsley M. Continuous positive airway pressure as adjunct treatment of acute altitude illness. High Alt Med Biol. 2013 Dec;14(4):405-7. doi: 10.1089/ham.2013.1059.</citation>
    <PMID>24377348</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centura Health</investigator_affiliation>
    <investigator_full_name>Todd Bolotin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

